Fig 1. Identification of RTK inhibitors that attenuate EBOV GP- and MARV GP-mediated virus growth.

(A) Titers of EBOVΔVP30-GFP from Vero VP30 cells in the presence of RTK inhibitors. Cells were treated with each RTK inhibitor at the indicated concentration (red line) or with 0.5% DMSO (black line) for 4 h prior to infection with EBOVΔVP30 at an MOI of 0.01. Virus titers were determined on days 3 and 6 post-infection. Data are presented as means ± SD of three independent experiments. (B and C) Virus titers (shown as bars) from Huh7.0 VP30 cells in the presence of RTK inhibitors. Cells were treated with the increasing doses of RTK inhibitors or with 0.5% DMSO for 4 h prior to infection with EBOVΔVP30 (B) or EBOVΔVP30-MARV GP (C) at an MOI of 0.01. Virus titers were determined on day 3 post-infection. In a separate set of experiments, viability of cells (shown as continuous lines) after treatment with inhibitors for 3 days was measured by means of a cell viability assay. Data are presented as means ± SD, and are representative of experiments performed in triplicate and repeated twice.